**Question:** In Philadelphia chromosome the defect is in -

A. BCR gene
B. ABL gene
C. SCL/TAL gene
D. JAK2 gene

**Core Concept:**
The Philadelphia chromosome is a specific chromosomal abnormality characterized by the fusion of two genes, specifically the breakpoint cluster region (BCR) and the Abelson (ABL) gene. This fusion leads to the formation of a constitutively active tyrosine kinase enzyme, causing uncontrolled cell division and leading to chronic myelogenous leukemia (CML).

**Why the Correct Answer is Right:**
The Philadelphia chromosome results from a translocation event between chromosomes 9 and 22, fusing the BCR gene on chromosome 9 with the ABL gene on chromosome 22. This fusion leads to the production of a chimeric protein with constitutive tyrosine kinase activity, promoting uncontrolled cell proliferation, and ultimately causing chronic myelogenous leukemia (CML).

**Why Each Wrong Option is Incorrect:**
A. The BCR gene is involved in the Philadelphia chromosome, but the correct answer is the ABL gene. BCR is just one component of the fusion protein formed with ABL.
B. The ABL gene itself is involved in the Philadelphia chromosome, but it is the BCR gene that forms the fusion with ABL to create the constitutively active tyrosine kinase enzyme.
C. SCL/TAL gene is not involved in the Philadelphia chromosome. The correct fusion is BCR-ABL, not SCL-ABL.
D. JAK2 gene is not involved in the Philadelphia chromosome. The correct fusion is BCR-ABL, not JAK2.

**Clinical Pearl:**
Understanding the molecular basis of Philadelphia chromosome is crucial for understanding the pathophysiology of chronic myelogenous leukemia (CML) and the development of targeted therapies like tyrosine kinase inhibitors (TKI), which are highly effective in treating CML. These drugs specifically target the constitutively active tyrosine kinase enzyme produced due to the BCR-ABL fusion gene.